Nymox Pharmaceutical Corp.

FDA panel votes 5-2 against kit form of NTP test

Published in Aging and Elder Health Week, August 21st, 2005

Nymox Pharmaceutical Corp. (NYMX) announced that on Friday, July 15, 2005, a U.S. Food and Drug Administration (FDA) advisory panel voted 5-2 against approval of the kit form of the company's neural thread protein (NTP) test (AlzheimAlert).

AlzheimAlert remains approved for sale in the U.S. as a laboratory testing service through the company's clinical reference laboratory in New Jersey. Nasdaq halted NYMX trading during the panel meeting in order to maintain an orderly market.

"We are very pleased to have had the opportunity to present the results of the blinded 9-center trial which showed that 89.5% of clinical cases of probable AD [Alzheimer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Aging and Elder Health Week

Source: Aging and Elder Health Week (2005-08-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry